Cytomis200 mcg

Cytomis 200 mcg is a synthetic prostaglandin E1 analogue with two distinct areas of use, each requiring completely different handling:

Prevention of NSAID-Induced Gastric Ulcers

• Reducing the risk of gastric ulcers in patients at high risk of complications from NSAID use (such as the elderly or those with a history of ulcer disease) who require ongoing NSAID therapy

Obstetric and Gynaecologic Use (Hospital/Medical Supervision Only)

• Prevention and treatment of postpartum haemorrhage, recognized by international bodies including WHO and FIGO, particularly where other uterotonic agents such as oxytocin are unavailable
• Cervical ripening and induction of labour in specific clinical circumstances, administered only by trained obstetric personnel in a hospital setting with fetal and uterine monitoring
• Management of early pregnancy loss (miscarriage) and, in combination with mifepristone under an approved medical protocol, termination of intrauterine pregnancy, always under direct medical supervision and in accordance with local law

All obstetric and gynaecologic uses of Cytomis 200 mcg require administration and monitoring by a qualified healthcare professional in an appropriate clinical setting; Cytomis 200 mcg should never be self-administered for these purposes.

Contains Cytomis 200 mcg as the active ingredient, available as oral tablets, commonly in 100 mcg and 200 mcg strengths. Some tablets are also administered by other routes (sublingual, buccal, vaginal, or rectal) under a healthcare professional's direction, using the same oral tablet formulation as directed by the treating clinician.

Cytomis 200 mcg is a synthetic prostaglandin E1 analogue with two very different clinical roles: at a low, regularly repeated oral dose, it protects the stomach lining in patients who need long-term NSAID therapy and are at high risk of ulcer complications; at other, higher doses and different routes, it is used by trained obstetric and gynaecologic teams for uterine indications, including prevention and treatment of serious bleeding after childbirth. Because Cytomis 200 mcg stimulates uterine contractions, it carries an absolute contraindication in pregnancy for its ulcer-prevention use, and all pregnancy-related uses require direct medical supervision, monitoring, and adherence to locally approved protocols.

Therapeutic Class: Prostaglandin E1 Analogue (Gastric Protectant / Uterotonic)

Cytomis 200 mcg is rapidly absorbed and de-esterified to its active form, Cytomis 200 mcg acid, which is responsible for both its gastric protective and uterotonic effects. It has a short elimination half-life, which is why the ulcer-prevention indication requires dosing up to 4 times daily to maintain protective effect throughout the day. Cytomis 200 mcg acid binds to prostaglandin EP3 receptors on uterine smooth muscle, which underlies its use in obstetric indications, and to gastric mucosal cells, where it reduces acid secretion and enhances the protective mucus and bicarbonate barrier.

• For NSAID ulcer prevention: take orally, with food, at the prescribed intervals throughout the day and at bedtime
• Avoid taking with magnesium-containing antacids, which can worsen Cytomis 200 mcg-associated diarrhoea
• For all obstetric and gynaecologic uses: administered only by, or under the direct supervision of, a trained healthcare professional in an appropriate clinical setting, following the specific route, dose, and monitoring protocol for the indication
• Before any obstetric use, abdominal examination is generally performed to confirm there is no additional fetus in utero

The following should be assessed by a healthcare professional before combining with Cytomis 200 mcg:

• Magnesium-containing antacids and other agents that cause diarrhoea: can worsen Cytomis 200 mcg-associated diarrhoea; generally avoided during ulcer-prevention therapy.
• Other uterotonic agents (such as oxytocin): when used together for obstetric indications, this combination requires careful specialist-level coordination, since it may increase the risk of adverse uterine effects without necessarily providing additional benefit.

Common side effects (ulcer-prevention use)

• Diarrhoea (a well-recognized, dose-related effect, usually mild to moderate and self-limiting)
• Abdominal pain or cramping
• Nausea, flatulence

Effects associated with obstetric use (under medical supervision)

• Fever, chills, shivering
• Uterine cramping and increased vaginal bleeding, expected as part of the intended effect

Serious effects (require prompt medical attention)

• Uterine tachysystole (excessive uterine contractions), which may impair placental blood flow and progress to uterine tetany
• Uterine rupture, particularly in women with a prior caesarean section or uterine surgery
• Amniotic fluid embolism (rare, serious)
• Excessive vaginal bleeding requiring emergency intervention

Pregnancy

Cytomis 200 mcg may cause birth defects, miscarriage, premature labour, or uterine rupture if given to pregnant women outside of a specific, medically supervised obstetric indication. It must not be used to reduce the risk of NSAID-induced ulcers in pregnant women, or in women of childbearing potential unless effective contraception is used and pregnancy is excluded. All pregnancy-related uses of Cytomis 200 mcg must occur under direct medical supervision, in accordance with an approved clinical protocol and local law.

Breastfeeding

Cytomis 200 mcg and its active metabolite are excreted in breast milk; the ulcer-prevention indication is generally not recommended during breastfeeding given limited safety data at this repeated dosing schedule. Use for obstetric indications immediately postpartum is directed by the medical team managing delivery, weighing the clinical urgency of the situation.

• Absolute pregnancy warning (ulcer-prevention use): Cytomis 200 mcg must not be taken by pregnant women for this indication; women of childbearing potential should have a negative pregnancy test before starting and use effective contraception throughout treatment.
• All obstetric and gynaecologic uses require direct medical supervision in an appropriate clinical setting with fetal and uterine monitoring by trained personnel - Cytomis 200 mcg should never be self-administered for pregnancy-related purposes.
• Prior caesarean section or uterine surgery: avoid using Cytomis 200 mcg for cervical ripening or labour induction in this group, given the significantly increased risk of uterine rupture.
• Safety and efficacy for the ulcer-prevention indication have not been established in patients with cardiovascular disease, diabetes, renal impairment, or respiratory disease.
• Cytomis 200 mcg should never be shared with, or given to, another person for use outside a doctor's direct guidance.

Overdose of Cytomis 200 mcg may cause sedation, tremor, seizures, difficulty breathing, abdominal pain, diarrhoea, fever, palpitations, low blood pressure, or slow heart rate; in pregnant women, overdose significantly increases the risk of severe uterine bleeding and complications. Suspected significant overdose is a medical emergency requiring immediate evaluation; treatment is generally supportive, provided in a medical facility, with close monitoring, particularly in pregnancy.

Store at room temperature (15-30°C), away from moisture, in the original container. Keep securely out of reach of children and anyone other than the person for whom it was prescribed, given the serious risks of unsupervised or accidental use in pregnancy.

• Women of childbearing potential (ulcer-prevention use): Require a negative pregnancy test before starting and effective contraception throughout treatment, given the absolute pregnancy contraindication for this indication.
• Elderly: Commonly the population most likely to need NSAID ulcer prevention; no specific dose adjustment beyond standard dosing is generally required for this indication.
• Renal or hepatic impairment: Specific safety data for the ulcer-prevention indication are limited in these populations; use with caution.

For NSAID ulcer prevention, Cytomis 200 mcg is continued for as long as NSAID therapy is needed. For obstetric indications, it is given as a single dose or a defined short course as part of a specific clinical protocol, determined entirely by the treating medical team based on the clinical situation.

Drug Class: Synthetic prostaglandin E1 (PGE1) analogue

In the stomach, Cytomis 200 mcg replaces the protective prostaglandins that NSAIDs block, reducing gastric acid secretion and enhancing mucus and bicarbonate production, which helps prevent NSAID-related ulcers. In the uterus, Cytomis 200 mcg stimulates prostaglandin EP3 receptors on uterine smooth muscle, producing contractions - this same action is used, under close medical supervision and monitoring, to help control bleeding after childbirth, prepare the cervix, or manage early pregnancy loss.

Cytomis 200 mcg is not established for use in children for either the ulcer-prevention or obstetric/gynaecologic indications, as these conditions and treatments apply to adult patients.